- Study meets primary endpoint demonstrating non-inferiority of roxadustat to darbepoetin in correction and maintenance of hemoglobin levels

Data simultaneously published in the New England Journal of Medicine and presented during the virtual scientific program of the 2020 ASCO Annual Meeting

XTANDI is now MHLW-approved for both metastatic hormone-sensitive prostate cancer and castration-resistant prostate cancer in Japan

Submission for the treatment of anemia in adult patients with chronic kidney disease

- Breakthrough Therapy Designation Based on Initial Results from Phase 1b/2 EV-103 Clinical Trial -

- After Median Follow-Up of 11.5 Months, 73 Percent of Patients Had Confirmed Tumor Response with Majority of Responses Still Ongoing; No New Safety Signals Observed for the Combination - - Findings To Be Presented During an Oral Session at the 2020 Genitourinary Cancers Symposium -

- New Funding will Address Disparities in Mental Health Diagnosis and Treatment for 400,000 People in Need -

- Combined company positioned to become a global leader in AAV-based genetic medicines, with Audentes to operate as a wholly-owned subsidiary and Center of Excellence for Astellas' newly created Genetic Regulation Primary Focus

Acquisition adds talent and proprietary therapeutic platform to accelerate next-generation cancer immunotherapy

- First-in-Class Antibody-Drug Conjugate Directed Against Nectin-4, a Protein Highly Expressed in Urothelial Tumors1,2 -

XTANDI is Now FDA-Approved for the Treatment of Metastatic Castration-Sensitive Prostate Cancer in Addition to Non-Metastatic and Metastatic Castration-Resistant Prostate Cancer

Catherine Levitt and Charlotte Stanton named to key global and regional senior roles

Two exciting biotechs win a year of access to life-science incubator and in-house Astellas expertise to advance their early drug discovery research

Emerging mutations in patients with treatment resistance, from Phase 3 ADMIRAL study, will be focus of oral presentation

- Companies to Initiate Phase 3 Trial to Support Global Registrations -

Approval based on Asian PREVAIL study of men with metastatic castration-resistant prostate cancer

- Results were published online and in the October 31 print edition of the Journal -

- Four innovators awarded $200,000 in total grants and resources following live pitch event to a panel of judges that included celebrity entrepreneur Bill Rancic -

Approval follows accelerated assessment, orphan designation by European Medicines Agency

Financial Support for LabCentral Incubators Builds on Astellas' $1 Billion+ Investment in Boston's Life Science Community

- Finalists will present their ideas during a live pitch event

- Study Met Outcomes for Safety and 71 Percent of Patients with Locally Advanced or Metastatic Urothelial (Bladder) Cancer Had a Confirmed Response -

- Astellas named Working Mother "100 Best Company" for fifth consecutive year -

If approved by the European Commission, gilteritinib would represent one of the few advances in Europe for AML over the past 40 years(1)

- US Employees Support 16 Local Organizations for Changing Tomorrow Day 2019 -

- Food & Drug Administration Sets Prescription Drug User Fee Action Date for March 15, 2020 -

Supporting pre-clinical scientific research: "Golden Ticket" sponsorship provides access to life-science incubator and in-house Astellas expertise for scientific entrepreneurs with cutting-edge ideas

XTANDI Supplemental New Drug Application (sNDA) Seeks to Add an Indication for Men with Prostate Cancer that Has Spread but Is Sensitive to Hormone Therapy

-Submission Based on Pivotal Phase 2 Trial Results Recently Presented at Annual Meeting of American Society of Clinical Oncology-

Glinski to Oversee US Sales for XTANDI

-First Investigational Therapy in a Pivotal Trial to Address Unmet Need for Patients with Advanced Urothelial Cancer After Treatment with Platinum Chemotherapy and a PD-1 or PD-L1 Inhibitor-

- Phase 3 ADMIRAL trial showed patients treated with XOSPATA demonstrated longer Overall Survival than those who received salvage chemotherapy[1] -

-Total Funds To Be Awarded Increased to $200,000; All Encouraged to Apply -

- Data Presented at the American Urological Association 2019 Annual Meeting -